A Study Study to Investigate the Effect on QT/QTc Interval of Moxifloxacin After a Single Dose in Healthy Male Subjects

The purpose of this study is to evaluate effect of moxifloxacin on QT/QTc interval in healthy male subjects. Moxifloxacin is a positive control drug used in QT study. In this study, moxifloxacin 400mg and 800mg will be used, (therapeutic and supratherapeutic doses) to get information on effect of moxifloxacin on QT/QTc interval in healthy Korean male subjects.

Inclusion criteria

• healthy male subject aged 20 to 40 at screening
• subjects who have weight over 50 kg with ideal body weight range of +- 20%
• subjects who decide to participate voluntarily and write a informed consent form

Exclusion criteria

• subjects who have acute illness within 28 days of investigational drug administration
• subjects who have clinically significant disease of cardiovascular, respiratory, renal, endocrinological, hematological, gastrointestinal, neurological(central nervous system), psychiatric disorders or malignant tumor
• subjects who have determined not eligible by screening test (medical history, physical examination, 12-lead ECG, laboratory test, etc) within 28 days of study start
• clinically significant allergic disease (except for mild allergic rhinitis)
• systolic blood pressure>= 140 mmHg, diastolic blood pressure >= 90 mmHg, heart rate > 100 bpm or < 50 bpm
• result of 12-lead electrocardiogram includes :

• QTcF > 450 msec
• PR interval > 200 msec or <110msec
• Evidence of second- or third-degree atrioventricular (AV) block
• Pathologic Q waves (defined as Q-wave > 40 msec or depth > 0.5 millivolt
• Evidence of ventricular pre-excitation, left bundle branch block (LBBB), right bundle branch block (RBBB)
• Intraventricular conduction delay with QRS > 120 msec
• risk of Torsade de pointes such as long QT syndrome, family history of sudden death, heart failure, hypokalemia
• Subjects considered unsuitable for inclusion by the investigator